Active Pharmaceutical Ingredients Market (2025 - 2030)

Active Pharmaceutical Ingredients Market Summary

In addition, advancements in biologics and biosimilars, along with innovative drug formulations, are further boosting the need for specialized APIs. Moreover, the shift toward generic medicines and the rise in contract manufacturing organizations (CMOs) are accelerating API production and distribution.

The global geriatric population is increasing. According to the UN, in 2023, people aged 65 and above accounted for around 771 million of the population, and the number is anticipated to reach 994 million by 2030 to 1.6 billion by 2050. The number of elderly people is showing the fastest growth in Africa, with a threefold increase estimated in people aged 60 and above, followed by Latin America, reaching 18.8 billion by 2050. Aging is considered the greatest risk factor for the development of diseases, including cardiovascular and neurological diseases. Thus, the rapidly growing global geriatric population is resulting in a high-impact-rendering driver for the API market.

The increasing prevalence of infectious diseases and hospital-acquired infections is driving market growth. In addition, the growing incidence of cardiovascular, genetic, and neurologic disorders is anticipated to act as a high-impact-rendering driver for market growth. Cardiovascular Diseases (CVDs) are the most prevalent causes of death globally. According to WHO, cardiovascular diseases cause the death of 17.9 million people per day and are expected to cause approximately 25 million deaths by 2030. Increasing epidemiology of lifestyle, aided by the rising number of smokers globally, growing incidence of obesity, and increasing dietary irregularities, are factors likely responsible for propelling market growth. A recent report by the United Nations (UN) in May 2023 suggests that there has been a 75% increase in the number of girls and 61% in the number of boys with obesity in Europe.

Outsourcing of APIs has become profitable over in-house production. However, this trend took a different turn during the COVID-19 pandemic. Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing them to just one manufacturer. In addition, risk mitigation is done using dual sourcing to ensure a continuous supply. Hence, key companies aim to capitalize on this ongoing outsourcing trend with new acquisitions. For instance, in August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry. This further demonstrates the company’s plans for vertical integration.

Type Of Synthesis Insights

Based on type of synthesis, the synthetic segment led the market with the largest revenue share of 71.08% in 2024. The primary driver behind the synthetic API market is the strong demand for generic drugs, which significantly contributes to revenue for companies involved in synthetic and chemical API manufacturing. This creates substantial opportunities for Contract Development and Manufacturing Organizations (CDMOs) operating in this segment. The appeal of the synthetic API market is further heightened for CDMOs due to the growing trend of outsourcing, as companies seek to enhance profitability by lowering production costs. In October 2023, Cambrex announced the completion of its USD 38 million small molecule API manufacturing facility, effectively doubling the size of its operations and improving its capacity to attract new customers to meet their changing requirements.

The biotech API segment is projected to experience at the fastest CAGR during the forecast period, driven by increasing investments in the biopharmaceutical and biotechnology sectors. These investments facilitate the development of new molecules that can effectively treat diseases like cancer. Major players are placing significant emphasis on biotech APIs due to their potential for high revenue generation and profitability. For instance, in May 2023, OLON Group announced its entry into the Antibody Drug Conjugate (ADC) API market with a new facility in Italy, investing €22 million (approximately USD 23.13 million) in production that meets a containment level of OEB6.

Type Insights

Based on type, the innovative APIs segment led the market with the largest revenue share of 63.20% in 2024. This growth can be attributed to increased funding and favorable regulations for research and development facilities. A number of novel products are currently in the pipeline due to extensive research in this area, with many expected to launch in the near future. In addition, growing support from regulatory agencies for the approval of new drugs is anticipated to further enhance market growth, reflecting a heightened focus by governments on healthcare and the pharmaceutical sector.

The generic APIs segment is expected to experience at the fastest CAGR during the forecast period. The expiration of patents for various branded molecules presents significant opportunities for the growth of generic API drugs. Following the pandemic, the pharmaceutical industry is approaching a patent cliff by 2030, with nearly 200 molecules scheduled to lose exclusivity and over 100 biosimilars currently in development as of 2023. This trend creates a favorable environment for generic API manufacturers, as the demand for these APIs is projected to increase significantly by the end of the decade. This includes more than 60 molecules within the oncology segment that are associated with complex, high-revenue-generating APIs.

Application Insights

Based on application, the cardiology segment led the market with the largest revenue share of 21.14% in 2024, driven by the increasing global prevalence of cardiovascular diseases (CVDs). According to the World Heart Report 2023, more than half a billion individuals worldwide are affected by CVDs, which accounted for approximately 20.5 million deaths in 2021-nearly a third of all global fatalities and an increase from the previously estimated 121 million deaths related to CVDs. Cardiovascular disease represents a significant public health challenge, prompting substantial research into APIs within this field. Notable APIs include Simvastatin, a cholesterol-lowering medication from the statin class used to treat dyslipidemia, and Rosuvastatin calcium, another API utilized for cardiovascular conditions by AstraZeneca.

The oncology segment is projected to experience at the fastest CAGR during the forecast period, driven primarily by the rising global prevalence of cancer. Collaborative efforts among pharmaceutical companies, research institutions, and regulatory bodies play a crucial role in accelerating drug development, ensuring patient safety, and promoting innovation. For instance, in March 2023, Pfizer Inc. and Seagen Inc. announced a definitive merger agreement whereby Pfizer plans to acquire Seagen, a leading biotech company focused on groundbreaking cancer therapies. This strategic transaction involves a cash payment of USD 229 per Seagen share, culminating in an enterprise value of USD 43 billion.

Type Of Manufacturer Insights

Based on type of manufacturer, the captive APIs segment led the market with the largest revenue share of 50.40% in 2024. An increasing number of companies are investing in overcoming challenges and developing new chemical methods for in-house API production. This approach helps lower costs and minimize the risk of contamination. Advances in protein synthesis and artificial intelligence are expected to enhance development by providing greater control over the manufacturing process. In addition, recent initiatives by major players show a strong inclination toward in-house production rather than outsourcing. For example, in September 2021, AstraZeneca announced a $360 million investment in its API manufacturing facility in Ireland to support the commercialization of innovative products. Such efforts from key industry players are expected to drive growth in this segment.

The merchant APIs segment is expected to experience at the fastest CAGR during the forecast period. A notable trend in the pharmaceutical sector is the increase in contract manufacturing and outsourcing of API molecule development. Given the high costs associated with the captive production of APIs, many companies are turning to outsourcing to reduce expenses. Merchant APIs offer a solution by eliminating the need for significant investments in costly equipment and advanced infrastructure. In the post-pandemic landscape, leading companies are enhancing their capacities to strengthen their market positions. For instance, in May 2023, Millipore Sigma announced a $69 million expansion of its facility in the U.S., which will double its manufacturing capacity for highly potent active pharmaceutical ingredients (HPAPIs). This facility will focus on the development and commercial manufacturing of antibody drug conjugates (ADCs).

Type Of Drug Insights

Based on type of drug, the prescription segment led the market with the largest revenue share of 79.15% in 2024. The demand for prescription drugs is significantly influenced by physicians' recommendations. The use of certain prescription medications, such as proton pump inhibitors (PPIs) for managing heartburn, has leveled off due to various side effects. In contrast, the prescription rates for Histamine-2 Receptor Antagonists (H2RAs) have also been affected. The oncology segment continues to rely heavily on prescription drugs, as cancer treatment predominantly involves chemotherapy, targeted therapies, immunotherapy, and hormonal therapies. In addition, the utilization of biologics is on the rise. The effectiveness of new targeted therapies has led to a rapid increase in prescriptions for these treatments, and major companies are actively introducing innovative targeted therapies to the market.

The OTC segment is projected to grow at a rapid CAGR during the forecast period. These products are easily accessible to consumers and are subject to fluctuations in consumer behavior. A growing trend indicates a movement away from antacids for heartburn, with an increasing focus on gut health through probiotics. This shift fosters greater opportunities for preventive health products, including supplements, nutraceuticals, and probiotics, while dampening the growth of traditional offerings.

Regional Insights

North America dominated the active pharmaceutical ingredients market with the largest revenue share of 38.04% in 2024, owing to the rising prevalence of cardiovascular, genetic, and other chronic diseases aided by growing research in the field of drug development. The presence of key players such as AbbVie Inc.; Curia; Pfizer Inc. (Pfizer Center One); Viatris Inc.; and Fresenius Kabi AG is positively influencing growth. For instance, in February 2022, Viatris received FDA approval for Generic Restasis-a cyclosporine ophthalmic emulsion for treating dry eye disease. The region shows high-value manufacturing areas, including complex & highly potent APIs, gene therapies & biologicals, which are expected to provide relative growth. Moreover, there is a significant expansion of innovators and CDMOs seen in the region, which is creating an expanded advantage for manufacturing and commercializing APIs.

U.S. Active Pharmaceutical Ingredients Market Trends

The active pharmaceutical ingredients market in the U.S. held a significant market share of North America in 2024, driven by strong pharmaceutical manufacturing capabilities and increasing demand for both generic and innovative APIs. The U.S. market benefited from advancements in biotechnology, particularly in the production of monoclonal antibodies, recombinant proteins, and vaccines. In addition, the rise of chronic diseases such as cancer, cardiovascular conditions, and diabetes further boosted API demand. The U.S. maintained its leadership in the region through a combination of cutting-edge API production, regulatory support, and an expanding biopharmaceutical sector.

Europe Active Pharmaceutical Ingredients Market Trends

The active pharmaceutical ingredients market in Europe is experiencing significant growth, driven by increasing demand for high-quality APIs across pharmaceutical applications, including both innovative and generic drugs. The region's strong regulatory framework, emphasizing stringent production standards, has significantly contributed to the market's expansion. In addition, the rise in chronic diseases such as cardiovascular and oncology-related conditions is fuelling API demand. Europe’s leadership in biotechnology has boosted the production of biotech APIs, including monoclonal antibodies, therapeutic enzymes, and vaccines. The growing focus on biosimilars and outsourcing to contract manufacturing organizations (CMOs) is further accelerating market growth.

The UK active pharmaceutical ingredients market is likely to grow at a significant CAGR during the forecast period, due to improvements in healthcare infrastructure and increasing demand for innovative and generic APIs. The rise in chronic diseases, including cardiovascular and oncology-related conditions, is driving API consumption. In addition, advancements in biotechnology and the production of biologics, along with supportive government policies, are further contributing to the market's expansion. The growing focus on biosimilars and contract manufacturing organizations (CMOs) is also expected to boost the UK's API market growth.

The active pharmaceutical ingredients market in Germany is experiencing significant growth, driven by strong pharmaceutical manufacturing capabilities and a robust regulatory framework. The increasing demand for both generic and innovative APIs, coupled with advancements in biotechnology, is propelling market expansion. In addition, the rise in chronic diseases and the growing focus on biosimilars are further enhancing the market's prospects.

Asia Pacific Active Pharmaceutical Ingredients Market Trends

The active pharmaceutical ingredients market in Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period. The market is experiencing sharp growth as the majority of API production occurs in countries present in the region with high API export rates. China is the largest producer of APIs, manufacturing over 1,600 varieties of chemical APIs. Moreover, several key global players are establishing their operations in the region. Rising investment and initiatives to support and expand manufacturing facilities are further driving the market growth. For instance, in November 2022, Aurobindo Pharma is expected to complete the Penicillin G plant approved under the PLI scheme by 2024, with an investment of USD 2,000 million to ensure and promote domestic manufacturing of API by increasing the production capacity to 15,000 tons annually.

The China active pharmaceutical ingredients market is anticipated to grow at a lucrative CAGR during the forecast period, driven by the expanding pharmaceutical industry and increasing domestic demand for both generic and innovative APIs. The government's support for healthcare reforms and investments in biotechnology are facilitating this growth. In addition, the rising prevalence of chronic diseases and an increasing focus on quality standards in API manufacturing are further propelling the market's expansion, positioning China as a key player in the global API landscape.

Latin America Active Pharmaceutical Ingredients Market Trends

The active pharmaceutical ingredients market in Latin America is experiencing significant progress, driven by rising healthcare investments and increasing demand for both generic and innovative APIs. The growing prevalence of chronic diseases and supportive regulatory environments are enhancing market growth, positioning the region as a developing hub for pharmaceutical production and development.

Middle East & Africa Active Pharmaceutical Ingredients Market Trends

The active pharmaceutical ingredients market in Middle East & Africa is experiencing growth driven by rising healthcare investments and an increasing focus on improving healthcare infrastructure. The demand for both generic and innovative APIs is on the rise due to the growing prevalence of chronic diseases in the region. In addition, supportive regulatory frameworks and collaborations with global pharmaceutical companies are enhancing the market's potential, making MEA a significant player in the global API landscape as it seeks to boost local production capabilities.

The Saudi Arabia active pharmaceutical ingredients market growth is driven by significant government initiatives aimed at enhancing the local pharmaceutical industry. Investments in healthcare infrastructure and a focus on reducing dependence on imports are fostering a favourable environment for API production. In addition, the increasing prevalence of chronic diseases and the demand for both generic and innovative APIs are further contributing to market expansion, positioning Saudi Arabia as a key player in the MEA API landscape.

Key Active Pharmaceutical Ingredients Company Insights

The competitive scenario in the active pharmaceutical ingredients industry is characterized by the presence of several key players, including large multinational pharmaceutical companies and specialized API manufacturers. These companies are focusing on innovation, quality assurance, and regulatory compliance to gain a competitive edge. Collaborations, mergers, and acquisitions are common strategies to enhance market share and expand product portfolios. In addition, the rise of biotechnology firms is intensifying competition, particularly in the biotech API segment. Regional players are also emerging, leveraging cost advantages and localized production to compete effectively.

Overall, the market is dynamic, with ongoing advancements and shifting player strategies shaping the competitive landscape. The presence of pipeline products in the API market is expected to launch in the coming years and is anticipated to drive market growth. A blockbuster drug patent expiration, increasing outsourcing activities due to high manufacturing costs, and stringent regulations on the production of APIs are expected to maintain the competitive rivalry at a high level during the forecast period.

Recent Developments

• In May 2024, Eli Lilly made a significant investment in its Lebanon, Indiana manufacturing site, increasing its total investment to USD 9 billion. This expansion aims to boost the production of active pharmaceutical ingredients (APIs) for tripeptide, the active ingredient in their drugs Zepbound and Mounjaro, which are used for treating obesity and type 2 diabetes.

• In April 2023, Eli Lilly announced an additional USD 1.6 billion investment in two new manufacturing plants in Indiana, raising its total commitment to USD 3.7 billion. This investment supports the production of its cancer drug Jaypirca and aims to enhance its capacity for treating obesity, Alzheimer's, and autoimmune diseases. Over the past three years, Lilly has invested USD 6.4 billion in U.S. manufacturing expansion.

• In January 2023, Sterling Pharma Solutions completed its acquisition of an active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, from Novartis, initially announced in March 2022. The facility enhances Sterling's API manufacturing capacity and includes an ongoing supply agreement with Novartis for cardiovascular, immunology, and oncology APIs. The site features multiple production buildings and extensive capabilities for handling potent APIs. This acquisition aligns with Sterling's growth strategy, expanding its workforce to 1,300 employees across five global facilities.

Active Pharmaceutical Ingredients Market